Year: 2024

Coop Pank’s financial results in November 2024:In November, number of the bank’s clients increased by 2,000 and number of active clients increased by 1,600. By the end of the month number of clients reached 206,000 and number of active clients reached 98,400. Over the year, customer base has grown by 14%. Volume of the bank’s customer deposits decreased by 37 million euros, reaching 1.84 billion euros by the end of month. Deposits of corporate customers decreased by 43 million euros and deposits of private customers increased by 1 million euros. The volume of deposits attracted from international platforms increased by 5 million euros. Over the year, volume of bank deposits has grown by 4%. The bank’s loan portfolio increased by 18 million euros and reached 1.70 billion euros by the end of month. Home loans increased...

Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously reported randomized controlled trial in adolescent and adult APDS patients Global regulatory filings planned to begin in 2025 Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib, marketed under the brand name Joenja® in the U.S., received approval from...

Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the USFirst non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by the combination vaccine candidates Paris, December 11, 2024. The US Food and Drug Administration has granted Fast Track designation to two Sanofi combination vaccine candidates to prevent influenza and COVID-19 infections in individuals 50 years of age and older. Both candidates combine two already licensed and authorized vaccines with proven efficacy through randomized controlled studies, and with favorable tolerability. The first combination vaccine candidate (NCT06695117) consists...

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved DMD therapy in ChinaPratteln, Switzerland, December 11, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that China’s National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for use in China in patients aged 4 years and older. “DMD is a devastating condition affecting over 70,000 families in China, and until now, there had been no approved treatment option for patients,” said Dario Eklund, CEO of Santhera. “We are delighted that NMPA has approved AGAMREE for the treatment of DMD in China and we look forward to working with our partner Sperogenix Therapeutics as it prepares...

Bayport Management Ltd is pleased to announce the refinancing of its existing senior and subordinated loan instruments and the utilisation of a super senior new money facility.AttachmentsBayport Management Limited – Press Release (New Money and Refinancing) – 11 Dec 2024Bayport Management Limited – Press Release (New Money and Refinancing) – 11 Dec 2024Bayport Management Limited – Press Release (New Money and Refinancing) – 11 Dec 2024

In cooperation with technology partner SITEC, Feintool was awarded a long-term contract in China related to hydrogen mobility. High-volume production of ready-to-install metallic bipolar plates for a leading Chinese manufacturer of fuel cells is expected to start in 2025. The bipolar plates ordered will be produced at Feintool’s specialized site in Taicang (China) and mainly installed in commercial vehicles, buses and cars. In addition to the core technologies FEINforming, Feintool’s patented process for high-precision metal processing, and FLEXwelding, automated laser welding developed by SITEC, our fully integrated coating and sealing processes are applied to this order. This allows the production of ready-to-install components for the customer. The order in China is further proof of the trust that customers operating in...

Press Release Nokia and SK Broadband deploy quantum secure network to protect Korea Hydro and Nuclear Power’s IT infrastructureDeployment allows Korea Hydro and Nuclear Plant (KHNP) to leverage quantum-safe MACsec technology to better protect its IP MPLS leased line network. Nokia’s trusted Quantum-Safe IP and optical network solutions enable KHNP to not compromise between security or performance with secure and trusted data network connectivity. Collaboration enhances ability to respond to accelerating cyber threats now and in the post-quantum era.11 December 2024Seoul, South Korea – Nokia today announced that Nokia and SK Broadband have deployed a leased line network for Korea Hydro and Nuclear Plant (KHNP) to enhance data security. Completed in August 2024, this deployment enables KHNP to protect its network against existing...

ARLINGTON, Va., Dec. 10, 2024 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced that it has upsized and priced an offering of $350.0 million aggregate principal amount of 2.25% convertible senior notes due 2030 (the “Notes”). The offering size was increased from the previously announced offering size of $300.0 million aggregate principal amount of Notes. The issuance and sale of the Notes are scheduled to settle on December 12, 2024, subject to customary closing conditions. Fluence also granted the initial purchasers of the Notes an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’...